argenx discontinues Phase 3 TED studies on efgartigimod SC due to futility
Compartilhar
Argenx (ARGX) announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod SC in Thyroid Eye Disease (TED) after an interim analysis by an Independent Data Monitoring Committee (IDMC) indicated futility.
